Search - tctmd.com

Displaying 941 - 960 of 1178

Sort: Relevancy | Date

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

Merck Calls Quits on CETP Inhibitor Anacetrapib

News Daily News

Merck Calls Quits on CETP Inhibitor Anacetrapib

Michael O'Riordan

October 12, 2017

Blood in Urine Carries Consequences for Patients on Antithrombotics

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

NOAC Bleeding Risk Rises With Several Drug Combinations

News Daily News

NOAC Bleeding Risk Rises With Several Drug Combinations

Michael O'Riordan

October 06, 2017

Generic ARBs Linked to Increased Adverse Events

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

TCTMD’s Top 10 Most Popular Stories for September 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

September 30, 2017

‘J-Curve’ in Hypertension May Be Explained by Differences in Patient Characteristics

News Daily News

‘J-Curve’ in Hypertension May Be Explained by Differences in Patient Characteristics

September 26, 2017

Quitting Chronic, Low-Dose Aspirin May Boost Risk of Cardiovascular Events

News Daily News

Quitting Chronic, Low-Dose Aspirin May Boost Risk of Cardiovascular Events

September 25, 2017

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

September 22, 2017

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

Ischemic Heart Disease the Leading Cause of Death Globally

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

Hormone Therapy Doesn’t Impact Long-term All-Cause, CV, or Cancer Mortality: WHI Analysis

News Daily News

Hormone Therapy Doesn’t Impact Long-term All-Cause, CV, or Cancer Mortality: WHI Analysis

September 14, 2017

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Clinical Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

Popular CV Risk Calculator Is Not Accurate Among Patients at Low Socioeconomic Standing

News Daily News

Popular CV Risk Calculator Is Not Accurate Among Patients at Low Socioeconomic Standing

Yael L. Maxwell

August 31, 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.